EE200200709A - Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine - Google Patents

Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine

Info

Publication number
EE200200709A
EE200200709A EEP200200709A EEP200200709A EE200200709A EE 200200709 A EE200200709 A EE 200200709A EE P200200709 A EEP200200709 A EE P200200709A EE P200200709 A EEP200200709 A EE P200200709A EE 200200709 A EE200200709 A EE 200200709A
Authority
EE
Estonia
Prior art keywords
fusion protein
composition containing
fusion
nucleic acid
acid encoding
Prior art date
Application number
EEP200200709A
Other languages
English (en)
Estonian (et)
Inventor
Neefe John
Goldstone Stephen
Winnett Mark
Siegel Marvin
Boux Leslie
Original Assignee
Stressgen Biotechnologies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stressgen Biotechnologies Corporation filed Critical Stressgen Biotechnologies Corporation
Publication of EE200200709A publication Critical patent/EE200200709A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Compounds Of Unknown Constitution (AREA)
EEP200200709A 2000-06-26 2001-06-26 Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine EE200200709A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21420200P 2000-06-26 2000-06-26
PCT/US2001/020240 WO2002000242A2 (fr) 2000-06-26 2001-06-26 Traitement des infections par le papillomavirus

Publications (1)

Publication Number Publication Date
EE200200709A true EE200200709A (et) 2004-08-16

Family

ID=22798190

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200709A EE200200709A (et) 2000-06-26 2001-06-26 Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine

Country Status (27)

Country Link
US (4) US20020110566A1 (fr)
EP (1) EP1296711B1 (fr)
JP (1) JP2004512264A (fr)
KR (2) KR100919266B1 (fr)
CN (1) CN100441223C (fr)
AT (1) ATE326236T1 (fr)
AU (3) AU2001271449B2 (fr)
BR (1) BR0111956A (fr)
CA (1) CA2413543A1 (fr)
CY (1) CY1105389T1 (fr)
CZ (1) CZ20024154A3 (fr)
DE (1) DE60119734T2 (fr)
DK (1) DK1296711T3 (fr)
EE (1) EE200200709A (fr)
ES (1) ES2263637T3 (fr)
HR (1) HRP20021015A2 (fr)
HU (1) HUP0301308A3 (fr)
IL (1) IL153474A0 (fr)
MX (1) MXPA02012858A (fr)
NO (1) NO20026044L (fr)
NZ (1) NZ523408A (fr)
PL (1) PL359930A1 (fr)
PT (1) PT1296711E (fr)
RU (1) RU2282461C2 (fr)
SK (1) SK18362002A3 (fr)
WO (1) WO2002000242A2 (fr)
ZA (1) ZA200210211B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP1196772A2 (fr) 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Stimulation d'une reponse de type th-1 in vitro
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
IL153474A0 (en) * 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
EP1363938B1 (fr) 2000-08-03 2013-12-11 Johns Hopkins University Vaccin moleculaire liant un polypeptide chaperon du reticulum endoplasmique a un antigene
WO2005090392A1 (fr) * 2004-03-16 2005-09-29 Inist Inc. Compositions tolerogenes a base de tat et methodes de production et d'utilisation associees
WO2002062959A2 (fr) 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Traitement du virus de l'hepatite b
US6649402B2 (en) * 2001-06-22 2003-11-18 Wisconsin Alumni Research Foundation Microfabricated microbial growth assay method and apparatus
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
KR101361769B1 (ko) * 2002-12-20 2014-02-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ-16 ｌ1 ｖｌｐ 및 ｈｐｖ-18 ｌ1 ｖｌｐ 백신
WO2004098526A2 (fr) 2003-05-05 2004-11-18 Johns Hopkins University Vaccin a adn anti-cancer faisant appel a des plasmides codant une sequence-signal, un antigene oncoproteine mutant, et une proteine de choc thermique
ES2427641T3 (es) 2003-05-22 2013-10-31 Ibio, Inc. Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
WO2005041880A2 (fr) * 2003-10-29 2005-05-12 Science & Technology Corporation @ Unm Rhpv comme modele des cancers induits par le papillomavirus humain
DE10357677A1 (de) * 2003-12-10 2005-07-14 Greiner Bio-One Gmbh Primer und Sonden zum Nachweis genitaler HPV-Genotypen
WO2005090968A1 (fr) * 2004-03-16 2005-09-29 Inist Inc. Compositions immunomoduatrices a base de tat, leur decouverte et leur utilisation
WO2006073970A2 (fr) 2005-01-06 2006-07-13 The Johns Hopkins University Interference arn bloquant l'expression de l'immunite potentialisee de proteines pro-apoptotiques induite par adn et des vaccins de cellules dendritiques transfectes
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
RU2283128C1 (ru) * 2005-04-05 2006-09-10 Сергей Викторович Луценко Способ получения препарата белка из семейства стрессовых и препарат белка hsp70, полученный этим способом
RU2285537C1 (ru) * 2005-04-05 2006-10-20 Автономная некоммерческая организация "Институт молекулярной диагностики (АНО "ИнМоДи") Противоопухолевый пептидный препарат на основе фрагмента альфа-фетопротеина, его конъюгат, фармацевтическая композиция и способ лечения гормонзависимых опухолей
US7807369B2 (en) * 2005-04-27 2010-10-05 Leiden University Medical Center Methods and means for the treatment of HPV induced intraepithelial neoplasia
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
CN101378781B (zh) * 2005-08-03 2013-08-07 美国弗劳恩霍夫股份有限公司 制造免疫球蛋白的组合物和方法
US7622121B2 (en) * 2005-09-21 2009-11-24 New York University Heat shock proteins from Mycobacterium leprae and uses thereof
AU2007215082B2 (en) * 2006-02-13 2012-07-12 Ibio, Inc. HPV antigens, vaccine compositions, and related methods
WO2008048344A2 (fr) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes
EP1984405A4 (fr) * 2006-02-13 2010-06-30 Fraunhofer Usa Inc Antigenes de la grippe, compositions de vaccins et procedes associees
RU2316342C1 (ru) * 2006-03-31 2008-02-10 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинная композиция для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, способ его получения
MX2008015293A (es) * 2006-05-31 2009-03-13 Nventa Biopharmaceuticals Corp Composiciones bioactivas purificadas de hspe7.
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
WO2008124483A1 (fr) * 2007-04-04 2008-10-16 Specigen, Inc. Immunothérapeutie utilisant des protéines-cages
US8778348B2 (en) * 2007-04-28 2014-07-15 Ibio Inc. Trypanosoma antigens, vaccine compositions, and related methods
US8404252B2 (en) 2007-07-11 2013-03-26 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
CA2696764A1 (fr) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Vaccins antigrippaux prophylactiques et therapeutiques, antigenes, compositions et procedes
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
WO2009094006A2 (fr) * 2007-10-25 2009-07-30 Wake Forest University Health Sciences Antigènes de protéine de membrane externe de bordetella et leurs procédés de fabrication et d'utilisation
EP2257301B1 (fr) 2008-03-03 2014-01-22 The University of Miami Immunothérapie à base de cellules cancéreuses allogéniques
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
RU2538683C2 (ru) * 2008-10-31 2015-01-10 Новартис Аг КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (Р13К) И ИНГИБИТОРА mTOR
ES2621141T3 (es) * 2008-11-28 2017-07-03 Novartis Ag Combinación farmacéutica que comprende un inhibidor de Hsp 90 y un inhibidor de mTOR
AU2010230073B2 (en) 2009-03-23 2016-05-26 Pin Pharma, Inc. Treatment of cancer with immunostimulatory HIV Tat derivative polypeptides
EP2483307A1 (fr) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Anticorps dirigés contre l'hémagglutinine du virus de la grippe, compositions, et procédés associés
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
US9662510B2 (en) 2010-07-19 2017-05-30 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
RU2438703C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинального суппозитория
RU2438652C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинального раствора для орошения, набор и способ его получения
RU2438702C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинальных капсул
KR20140045341A (ko) * 2011-02-23 2014-04-16 유니버시티 오브 마이애미 Siv/hiv로부터의 보호를 위한 조합된 세포 기반의 gp96-ig-siv/hiv, 재조합 gp120 단백질 백신접종
US9028884B2 (en) 2013-08-13 2015-05-12 Preventamedics LLC Medical delivery devices and methods for applying a barrier composition to a targeted skin surface
EP3052127A1 (fr) 2013-10-04 2016-08-10 PIN Pharma, Inc. Polypeptides immunostimulants dérivés du tat de vih utilisés dans le traitement du cancer
GB2541749B (en) 2015-08-31 2020-12-09 Emblation Ltd An interference suppression apparatus and method
US11497926B2 (en) 2016-08-08 2022-11-15 Emblation Limited Method and apparatus for the treatment, management and/or control of pain
US11980769B2 (en) 2017-03-28 2024-05-14 Emblation Limited Stenosis treatment
JP7457642B2 (ja) * 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
CN108409866A (zh) * 2018-01-23 2018-08-17 合肥瑞城生生物科技有限公司 一种用于治疗和预防人乳头瘤病毒感染及相关疾病的多表位组合肽
FI3833378T3 (fi) * 2018-08-06 2025-06-16 Nielsen Biosciences Inc Syylien hoito
EP3909612A1 (fr) * 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition de nanoparticules
CN114478712B (zh) * 2022-03-29 2022-09-23 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666847A (en) * 1981-01-16 1987-05-19 Collaborative Research, Inc. Recombinant DNA means and method
NO172595C (no) 1983-02-07 1993-08-11 Battelle Memorial Institute Fremgangsmaate og ekspresjonsplasmid for fremstilling av hemagglutinin under kontroll av drosophila hsp-promoter
US4797359A (en) * 1983-05-10 1989-01-10 Board Of Regents, The University Of Texas System Heat shock regulated production of selected and fused proteins in yeast
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4784941A (en) * 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
EP0230222A1 (fr) 1986-01-06 1987-07-29 F. Hoffmann-La Roche Ag Expression du gène gag de HTLV-III
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4906742A (en) 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
AU1548388A (en) 1987-02-02 1988-08-24 Whitehead Institute For Biomedical Research Mycobacterium tuberculosis genes and encoding protein antigens
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5256767A (en) * 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5204259A (en) * 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
EP0419569B1 (fr) 1988-06-15 1995-09-06 Whitehead Institute For Biomedical Research Proteines de stress et leurs utilisations
AU5184190A (en) 1989-02-23 1990-09-26 University Of Ottawa Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
CA2063414A1 (fr) 1989-06-19 1990-12-20 Richard A. Young Insertion d'un genome a l'aide d'un vecteur et expression de l'adn dans le bcg
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
CA2095855C (fr) 1990-11-08 2003-04-29 Graham A.W. Rook Emploi de mycobacterium comme adjuvant a des antigenes
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
EP0521220A1 (fr) 1991-06-14 1993-01-07 Institut Pasteur Actinomycétale immunogène recombinant
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993022343A1 (fr) 1992-05-01 1993-11-11 The Rockfeller University Systeme antigenique a plusieurs peptides possedant des proprietes d'adjuvant, vaccins prepares a partir dudit systeme
GB9211736D0 (en) 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5736146A (en) 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
ATE212378T1 (de) 1993-06-04 2002-02-15 Whitehead Biomedical Inst Stressproteine und ihre verwendung
US5404142A (en) 1993-08-05 1995-04-04 Analog Devices, Incorporated Data-directed scrambler for multi-bit noise shaping D/A converters
US5925362A (en) * 1993-08-11 1999-07-20 Jenner Technologies Method to elicit an antitumor response with human prostate-specific antigen
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
IL109790A0 (en) 1994-05-25 1994-08-26 Yeda Res & Dev Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
WO1996026277A1 (fr) 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides utiles comme agents immunotherapeutiques et procedes de preparation de polypeptides
AU724399B2 (en) 1995-08-18 2000-09-21 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
WO1997026910A2 (fr) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Vaccin antitumoral pour le traitement immunitaire des tumeurs malignes
FI990157A0 (fi) * 1996-07-29 1999-01-28 Cantab Pharma Res Immunoterapeuttisina aineina käyttökelpoisia polypeptidejä sekä polypeptidivalmistuksen menetelmiä
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
JP4484969B2 (ja) 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
EP1047451A1 (fr) 1997-02-18 2000-11-02 Whitehead Institute For Biomedical Research Utilisation de proteines de choc thermique pour introduire des fractions dans des cellules
ATE231917T1 (de) * 1997-08-05 2003-02-15 Stressgen Biotechnologies Corp Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CN1248631A (zh) * 1998-09-24 2000-03-29 周国庆 一种免疫预防和免疫治疗性病和癌症的融合蛋白
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6497880B1 (en) * 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
EP1196772A2 (fr) * 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Stimulation d'une reponse de type th-1 in vitro
EP1218030A4 (fr) 1999-09-10 2004-09-15 Univ Fordham Procedes et compositions pour le traitement et la prevention des rejets de greffes utilisant des proteines de choc thermique
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
WO2001052877A1 (fr) 2000-01-21 2001-07-26 University Of Connecticut Health Center Compositions et techniques pour traiter des troubles neurodegeneratifs
WO2001052890A1 (fr) 2000-01-21 2001-07-26 University Of Connecticut Health Center Complexes de proteines de choc thermique/stress utilises en tant que vaccins contre les troubles neurodegeneratifs
AU2001229592A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
IL153474A0 (en) * 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment

Also Published As

Publication number Publication date
HUP0301308A3 (en) 2010-01-28
NO20026044D0 (no) 2002-12-16
AU2001271449B2 (en) 2006-08-24
CN100441223C (zh) 2008-12-10
WO2002000242A8 (fr) 2003-03-13
WO2002000242A2 (fr) 2002-01-03
MXPA02012858A (es) 2004-04-20
US20030170268A1 (en) 2003-09-11
ES2263637T3 (es) 2006-12-16
US20020110566A1 (en) 2002-08-15
US7754449B2 (en) 2010-07-13
NO20026044L (no) 2003-02-20
CA2413543A1 (fr) 2002-01-03
JP2004512264A (ja) 2004-04-22
CY1105389T1 (el) 2010-04-28
NZ523408A (en) 2006-02-24
EP1296711B1 (fr) 2006-05-17
AU7144901A (en) 2002-01-08
AU2006203436A1 (en) 2006-08-31
RU2282461C2 (ru) 2006-08-27
EP1296711A2 (fr) 2003-04-02
KR20030025939A (ko) 2003-03-29
SK18362002A3 (sk) 2004-02-03
DE60119734D1 (de) 2006-06-22
HUP0301308A2 (hu) 2003-08-28
HRP20021015A2 (en) 2004-02-29
PT1296711E (pt) 2006-08-31
US6797491B2 (en) 2004-09-28
ZA200210211B (en) 2004-03-17
DE60119734T2 (de) 2007-04-26
US20040235741A1 (en) 2004-11-25
CZ20024154A3 (cs) 2003-08-13
US7211411B2 (en) 2007-05-01
DK1296711T3 (da) 2006-08-28
KR100919266B1 (ko) 2009-09-30
WO2002000242A3 (fr) 2002-10-03
PL359930A1 (en) 2004-09-06
CN1678344A (zh) 2005-10-05
ATE326236T1 (de) 2006-06-15
US20080063661A1 (en) 2008-03-13
IL153474A0 (en) 2003-07-06
KR20080075560A (ko) 2008-08-18
BR0111956A (pt) 2003-05-13

Similar Documents

Publication Publication Date Title
IL153474A0 (en) Human papilloma virus treatment
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
ATE430200T1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
NO329875B1 (no) Isolert DNA-sekvens som koder for svinereproduktive- og respiratoriske syndromvirus (PRRSV), en sammensetning omfattende polypeptidene kodet av denne, en sammensetning for indusering av antistoffer mot PRRSV, anvendelse av sammensetning for fremstilling av vaksine og fremgangsmate for a skille PRRSV-stamme ISU-55 fra andre PRRSV-stammer.
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
ATE404220T1 (de) Rekombinierte pockenvirus-tollwut zusammensetzung und kombinierte zusammensetzungen und deren verwendung
EP0330359A3 (fr) Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
CY1112171T1 (el) Μτβ32α αντιγονο μυκοβακτηριδιου της φυματιωσης με απενεργοποιημενη δραστικη θεση και πρωτεϊνες συντηξης αυτου
EA200000860A1 (ru) Выделенный полинуклеотид (варианты), полинуклеотид (варианты), вектор (варианты), клетка-хозяин (варианты), выделенный полипептид (варианты), способ его получения (варианты), вакцинная композиция (варианты), способ терапевтического или профилактического лечения стрептококковой бактериальной инфекции у животного (варианты), применение (варианты)
UA35639C2 (uk) Спосіб одержання композиції очищеного капсидного білка вірусу папіломи людини
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
DE69523055D1 (de) T-zellen stimulierendes protein von pestivirus
EA200200743A1 (ru) Рекомбинантное ослабление вируса репродуктивного и респираторного синдрома свиней (prrsv)
WO1998023752A3 (fr) Papillomavirus, agents pour les depister et pour traiter des maladies causees par ces virus
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
ATE328897T1 (de) Verwendung von hev-polypeptiden

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name